Bristol Sends Pravachol Corrective Letter To Statin Prescribers, Patients
This article was originally published in The Pink Sheet Daily
Bristol takes out full-page corrective newspaper ads clarifying Pravachol’s indication. The ad also references the approval of Merck’s Zocor, which carries the same indication as Pravachol.
You may also be interested in...
The DTC campaign misled consumers into purchasing pravastatin, the proposed class action complaint says. FDA challenged the claim that Pravachol would help prevent stroke in patients without heart disease in an August 2003 warning letter.
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.